Pfizer Inc
Latest Pfizer Inc News and Updates
How Merck’s Business Segments Performed
Merck reported 3% growth in revenues to ~$10.4 billion during 4Q17 as compared to 4Q16.
A Look at Novartis’s Immunology and Dermatology Segment’s Performance
In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.
GlaxoSmithKline’s Valuations after Its 4Q17 Earnings
On February 15, 2018, GlaxoSmithKline traded at a forward PE multiple of 12.9x, which is lower than the industry average of 13.3x.
Kymriah May Emerge as a Robust Treatment Option in DLBCL Indication
Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.
Inside Pfizer’s Rare Disease Segment Performance in 2017
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
How Pfizer’s Peri-LOE Products Performed in 2017
Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.
Inside Pfizer’s Vaccines Performance in 4Q17 and 2017
In 4Q17, Pfizer (PFE) generated revenues of $1.6 billion from the sale of vaccines, which reflected a ~8% rise on a YoY (year-over-year) basis.
Pfizer’s Bosulif Had a Strong Performance in 4Q17 and 2017
In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.
GSK Has Emerged as Leading Player in Over-the-Counter Market
GlaxoSmithKline (GSK) is currently the leader in the 135 billion pound consumer healthcare market.
Johnson & Johnson’s Pharmaceuticals Business in 4Q17
Johnson & Johnson (JNJ) reported ~48.0% of its total revenues from the Pharmaceuticals business during 4Q17, making it the company’s largest revenue contributor.
Pfizer’s 4Q17 Estimates: Products with Lower Sales
In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.
GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017
GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments.
A Strong Pipeline of Drugs Bodes Well for Radius Health
The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.
Tasigna Could Boost Novartis’s Revenue Growth in 2018
In 1Q17, 2Q17, and 3Q17, Tasigna generated revenues of $411 million, $463 million, and $482 million, respectively.
Novartis’s Crizanlizumab Demonstrates Positive Results in Trials
In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.
Analyst Ratings and Recommendations for Johnson & Johnson
JNJ stock has risen 27.9% in the last 12 months. Analysts estimate that the stock could rise 1.4% over the next 12 months.
Johnson & Johnson’s Medical Devices Segment: 4Q17 Estimates
Johnson & Johnson’s (JNJ) Medical Devices segment includes products for specialty surgery, orthopedics, cardiovascular care, surgical care, diabetes care, and vision care.
Johnson & Johnson’s Consumer Segment: 4Q17 Estimates
Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International.
How Amgen’s Enbrel and Nplate Are Positioned for 2018
In 1Q17, 2Q17, and 3Q17, Amgen’s (AMGN) Enbrel generated revenues of ~$1.2 billion, ~$1.5 billion, and ~$1.4 billion, respectively.
Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline
On January 10, 2018, Vertex Pharmaceuticals announced that Orkambi has secured regulatory approval from the European Commission to treat CF patients ages six to 11 years.
Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth
In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.
How Is Bioverativ’s Eloctate Positioned Now?
In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.
What to Expect from Roche’s Investigational Drug Polatuzumab Vedotin
In December 2017, Roche (RHHBY) presented the results of its randomized phase two GO29365 trial.
How Incyte’s Jakafi Performed in 3Q17
Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.
Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
On December 20, 2017, AbbVie (ABBV) reported positive top-line results from its phase-3 trial Select-Monotherapy.
What Upadacitinib Did for AbbVie in 2017
In September 2017, AbbVie’s (ABBV) investigational immunology drug, Upadacitinib (ABT-494), managed to demonstrate its clinical potential.
A Look at Pfizer’s Valuation
Pfizer (PFE) reported revenue of $13.2 billion in 3Q17, ~1% growth from its 3Q16 revenue of $13.0 billion.
How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
Pfizer Is Pursuing Oncology, Inflammation, and Immunology Research
On May 9, 2017, the US Food and Drug Administration (or FDA) approved Pfizer (PFE) and Merck’s Bavencio (avelumab) as a treatment option for patients suffering from locally advanced or metastatic urothelial carcinoma (or UC).
How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017
In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.
How the Medical Expense Tax Deduction Affects the Healthcare Industry
According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.
A Look at How These Pfizer Drugs Have Performed in 2017
In 3Q17, Pfizer’s (PFE) Celebrex generated revenues of $212 million, a ~9% increase on a year-over-year (or YoY) basis and a 19% increase on a quarter-over-quarter basis.
Keytruda: Driving Merck’s Growth
For 3Q17, Keytruda reported revenues of ~$1.1 billion, a 194% growth compared to revenues of $356 million in 3Q16.
Eli Lilly’s Cialis and Other Cardiovascular Products in 3Q17
Eli Lilly’s cardiovascular franchise includes the drugs Cialis and Effient, but for 3Q17, both drugs reported lower sales.
Could Lorlatinib Be a Long-Term Growth Driver for Pfizer?
Lorlatinib is Pfizer’s (PFE) investigational next-generation ALK/ROS-1 tyrosine kinase inhibitor in clinical trials to evaluate its safety and efficacy in the treatment of ALK-positive metastatic non-small cell lung cancer.
Merck’s Immunology and Oncology Drugs, Post-3Q17
Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]
Behind Exelixis’s Cabometyx Strategy for 2018
Exelixis (EXEL) expects the FDA’s approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.
These Pfizer Products Lost Market Share in 3Q17
BeneFIX revenues fell 14% to $151 million during 3Q17, driven by a 16% fall in international sales to $87 million.
What Do Analysts Think about Merck?
Wall Street analysts estimate Merck’s (MRK) top line will increase marginally by 0.1% to ~$10,546 million in 3Q17.
Inside Pfizer’s Performance in 3Q17
PFE stock rose ~7.3% in 3Q17 and has risen ~11.3% YTD (year-to-date) as of October 16.
Bristol-Myers Squibb’s Immunoscience Products
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.
These Factors Affected Johnson & Johnson’s Revenues in 2Q17
Johnson & Johnson (JNJ) reported a 2.9% increase in its revenues at constant exchange rates in 2Q17.
These Pfizer’s Products Are Now Losing Market Share
Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.
How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.
An Update on Novartis’s Sandostatin, Afinitor, and Exjade
In 1H17, Novartis’s (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.
How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?
In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.
Kisqali Could Significantly Boost Novartis’s Revenue Growth
In 1H17 and 2Q17, Novartis’s (NVS) Kisqali reported revenues of around $15 million and $8 million, respectively.
Could Mylan See a Rise in Net Profit Margins in 2017?
In 2Q17, Mylan (MYL) reported gross profit margins of 54.0%, which was lower than 56.0% reported in 2Q16.
What Analysts Recommend for Novartis in September 2017
Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”
Management Changes at Baxter International: What You Should Know
Baxter International (BAX) has been going through a cost transformation and reorganization process for some time. The initiative includes some leadership and management changes.